The present invention relates to the use of at least one compound comprising the amino acid sequence €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ (X 1 ) n X 2 X 3 PVX 4 X 5 X6(X 7 ) m €ƒ€ƒ€ƒ€ƒ€ƒ(Formula 1), wherein X 1 is any amino acid residue, X 2 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E), X 3 is any amino acid residue, X 4 is any amino acid residue, X 5 is an amino acid residue selected from the group consisting of proline (P) and alanine (A), X 6 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E), X 7 is any amino acid residue, n and m, independently, are 0 or an integer of more than 0, and wherein the amino acid sequence according to Formula I is not identical with, or does not comprise the 8-mer polypeptide fragment of alpha-synuclein having the amino acid sequence DMPVDPDN, said compound having a binding capacity to an antibody which is specific for an epitope of alpha-synuclein comprising the amino acid sequence DMPVDPDN for producing a medicament for preventing and/or treating synucleinopathies.
